Sanford Bernstein Upgrades Genzyme (GENZ) to Outperform
More News related to GENZ
- Notable Analyst Rating Changes 7/1: SIRI, AXP, NVDA, CTAS Upgraded; FO, ALTR, RBN Downgraded
- UBS Starts Genzyme (GENZ) at Buy
- Genzyme and Isis Complete Licensing of Mipomersen
- SAFE-BioPharma Roaming Digital ID Is First to Be Accepted by Federal Bridge
- Deutsche Bank Starts Genzyme (GENZ) at Hold
Sanford Bernstein upgrades Genzyme (Nasdaq: GENZ) from Market Perform to Outperform. Price target $90.
Genzyme Corporation is a biotechnology company.
Related Categories
UpgradesStocks Mentioned
+0.57Related Entities
Sign up for StreetInsider Free!
Recieve full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
